Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Global Climate Change

Global Climate Change

Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.

Distance Corrections

Distance Corrections

To achieve precise distance measurements, especially in surveying and construction, certain corrections must be applied to account for potential sources of error like the standardization errors, temperature variations, and slope adjustments.Standardization error emerges when measurement equipment undergoes changes, such as wear, repairs, or weather impacts. To address this, surveyors compare the equipment’s readings to a standard. This process identifies any deviation that might lead to...

Power Factor Correction

Power Factor Correction

The power transmission to a factory involves the transfer of apparent power, a combination of active and reactive power. The power factor measures how effectively electrical power is converted into useful work output. The ratio of the real power (KW) that does the work to the apparent power (KVA) supplied to the circuit.

Introduction to Global Positioning System

Introduction to Global Positioning System

The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...

Errors in Global Positioning System

Errors in Global Positioning System

Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Leniolisib: First Approval.

Drugs·2023

Same author

Sugemalimab: First Approval.

Drugs·2022

Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022

Same author

Abrocitinib: First Approval.

Drugs·2021

Same author

Vosoritide: First Approval.

Drugs·2021

Same author

Donafenib: First Approval.

Drugs·2021

Search research articles

Related Experiment Video

Updated: Feb 1, 2026

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Published on: July 8, 2025

Correction to: Caplacizumab: First Global Approval.

¹Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|December 5, 2018

Summary

This summary is machine-generated.

Caplacizumab has received its first global approval, marking a significant advancement in treatment options. This development offers new hope for patients with previously limited therapeutic avenues.

More Related Videos

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Related Experiment Videos

Last Updated: Feb 1, 2026

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Surgical Correction for Pediatric Epiblepharon and Trichiasis

Published on: July 8, 2025

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

Area of Science:

Hematology
Pharmacology

Background:

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune disease.
Characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.

Purpose of the Study:

To report the first global approval of Caplacizumab.
To highlight its significance in the therapeutic landscape for aTTP.

Main Methods:

Review of regulatory submission data.
Analysis of clinical trial outcomes for Caplacizumab in aTTP patients.

Main Results:

Caplacizumab demonstrated efficacy in reducing thrombotic microangiopathy events.
Safety profile consistent with previous clinical studies.

Conclusions:

The approval of Caplacizumab represents a major milestone in aTTP management.
Offers a targeted therapy option for patients with this critical condition.